Ypsomed Divests Pen Needle: Focuses on Insulin Pump Innovation

Ypsomed se desprende de Pen Needle: Se centra en la innovación en bombas de insulina

Jue, 28 mar 2024

Ypsomed traspasa el negocio de agujas para pluma y BGM a MTD, canalizando la inversión hacia la ampliación de la planta de Solothurn y la mejora de las soluciones para bombas de insulina.

Ypsomed, a notable player in the healthcare sector, has divested its pen needle and glucose monitoring systems (BGMs) segment to Medical Technology and Devices S.p.A. (MTD) según un comunicado de prensa.

This decision is aligned with Ypsomed’s vision to concentrate on advancing and commercialising its cutting-edge mylife Loop insulin pump solution. The transition to MTD, anticipated to finalise in summer 2024, is set to ensure a continuous supply of high-quality pen needles, catering to the global demand from insulin and hormone injectors.

In the interim, Ypsomed will continue manufacturing pen needles under a contract arrangement, facilitating a smooth transition by mid-2025. This business segment, now transitioning to MTD, recorded sales of over CHF 50 million in the fiscal year 2022/23, with a subsequent CHF 18 million in the first half of FY 2023/24.

MTD aims to enrich its portfolio with Ypsomed’s acclaimed click technology and its own 34G pen needle, envisioning expanded market reach and enhanced service to the diabetes community.

Ypsomed is set to channel over CHF 100 million into its Solothurn site over the next four years, boosting autoinjector production capabilities. This expansion will not only augment its manufacturing capacity but also introduce a new injection moulding tool shop, thereby creating numerous job opportunities.

Ypsomed assures its workforce of continued employment and is actively seeking avenues to accommodate all employees affected by the business transition within the group or through partner recruiting agencies.

Historias relacionadas

Organic Farming Expansion in Swiss Agriculture

14 mayo 2024

Organic farming gains ground in Switzerland, increasing its reach across farm units and agricultural land, despite a...

Swiss Running Shoe Brand On: Record Breaking Quarter

14 mayo 2024

On Running's turnover exceeds CHF 500 million in Q1 2024, with sales up 21% and net profit more than doubling. Positive...

Switzerland Expands Tax Transparency to Include Crypto Assets

16 mayo 2024

Switzerland extends AEOI coverage to crypto assets, enhancing financial transparency and regulatory compliance starting...

Logitech May Increase Dividends

15 mayo 2024

Logitech to boost its dividend to CHF 1.16 per share for 2023/24, reflecting robust financial health and shareholder...

Alcon, Swiss Pharmaceutical Firm Growth Slows

14 mayo 2024

Alcon sees a 5% increase in Q1 sales, achieving $2.44 billion with profits surging to $248 million, despite a minor...

Swiss Re Exceeds Expectations with Strong Q1

16 mayo 2024

Swiss Re kicks off 2024 with impressive Q1 earnings of $1.09 billion, outpacing estimates thanks to a strong investment...

Novartis Successfully Secures Takeover of German Biotech Firm Morphosys

16 mayo 2024

Novartis meets key conditions in Morphosys takeover, achieving 79.6% acceptance and gearing up for final integration...

Mantente en contacto

Cabe destacar

Swiss Media Empire TX Group Layoffs Staff

Cabe destacar

7 mayo 2024

Swiss Media Empire TX Group Layoffs Staff

Swiss National Bank Record Profits in Q1 2024: UBS Analysts Predict

Cabe destacar

22 abril 2024

Ypsomed se desprende de Pen Needle: Se centra en la innovación en bombas de insulina

Ypsomed se desprende de Pen Needle: Se centra en la innovación en bombas de insulina

Historias relacionadas

Mantente en contacto

Cabe destacar

Swiss Media Empire TX Group Layoffs Staff

Beneficios récord del Banco Nacional Suizo en el primer trimestre de 2024: Predicción de los analistas de UBS

Enlaces rápidos